eamdacademy.org-owEg-1793544576-l252254324 1793544576 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2026 5 2 Thabo Nkosi Lerato Molefe Sipho Dlamini Ayanda Mokoena Kabelo Ndlovu 2026 10.68159/l252254324 https://eamdacademy.org/pub/journal/3/article/l252254324 Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-24. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37. Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA, et al. Targeted drug delivery strategies for precision medicines. Nat Rev Mater. 2021;6(4):351-70. Dutta D, Heo I, Clevers H. Disease modeling in stem cell-derived 3D organoid systems. Trends Mol Med. 2017;23(5):393-410. Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1):373-86. Yan HH, Siu HC, Law S, Ho SL, Yue SS, Tsui WY, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 2018;23(6):882-97. Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, et al. An organoid platform for ovarian cancer captures intra-and interpatient heterogeneity. Nat Med. 2019;25(5):838-49. Driehuis E, van Hoeck A, Moore K, Kolders S, Francies HE, Gulersonmez MC, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci USA. 2019;116(52):26580-90. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920-6. Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8(9):1112-29. Ooft SN, Weeber F, Dijkstra KK, McLean CM, Kaing S, van Werkhoven E, et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci Transl Med. 2019;11(513):eaay2574. Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell. 2020;26(1):17-26. Wensink GE, Elias SG, Mullenders J, Koopman M, Boj SF, Kranenburg OW, et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. NPJ Precis Oncol. 2021;5(1):30. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410. Bose S, Clevers H, Shen X. Promises and challenges of organoid-guided precision medicine. Med. 2021;2(9):1011-26. Artegiani B, Clevers H. Use and application of 3D-organoid technology. Hum Mol Genet. 2018;27(R2):R99-107. Verduin M, Hoeben A, De Ruysscher D, Vooijs M. Patient-derived cancer organoids as predictors of treatment response. Front Oncol. 2021;11:641980. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-94. Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater. 2017;2(10):17056. Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27(4):710-28. Lancaster MA, Huch M. Disease modelling in human organoids. Dis Model Mech. 2019;12(7):dmm039347. Prasad M, Kumar R, Buragohain L, Kumari A, Ghosh M. Organoid technology: a reliable developmental biology tool for organ-specific nanotoxicity evaluation. Front Cell Dev Biol. 2021;9:696668. Nabi SU, Ali SI, Rather MA, Sheikh WM, Altaf M, Singh H, et al. Organoids: A new approach in toxicity testing of nanotherapeutics. J Appl Toxicol. 2022;42(1):52-72. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019;4(3):e10143. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-79. Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19(5):566-75. Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407-18. He W, Sun Q, Ge D, Liu Y, Sun B. Application of nanomaterials in organoid culture and cryopreservation. Nanoscale Adv. 2025;7(23):7483-503. Desai D, Åkerfelt M, Prabhakar N, Toriseva M, Näreoja T, Zhang J, et al. Factors affecting intracellular delivery and release of hydrophilic versus hydrophobic cargo from mesoporous silica nanoparticles on 2D and 3D cell cultures. Pharmaceutics. 2018;10(4):237. Baek A, Kwon IH, Lee DH, Choi WH, Lee SW, Yoo J, et al. Novel organoid culture system for improved safety assessment of nanomaterials. Nano Lett. 2024;24(3):805-13. Mergani A, Meurer M, Wiebe E, Dümmer K, Wirz K, Lehmann J, et al. Alteration of cholesterol content and oxygen level in intestinal organoids after infection with Staphylococcus aureus. FASEB J. 2023;37(12):e23279. Ren X, Huang M, Weng W, Xie Y, Wu Y, Zhu S, et al. Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application. Cell Rep Med. 2023;4(11):101238. Zhao Y, Li S, Zhu L, Huang M, Xie Y, Song X, et al. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer. Cell Rep Med. 2024;5(7):101622. Eygeris Y, Henderson MI, Curtis AG, Jozić A, Stoddard J, Reynaga R, et al. Preformed vesicle approach to LNP manufacturing enhances retinal mRNA delivery. Small. 2024;20(37):2400815.